PDS Biotechnology Corporation (PDSB)
PDSBNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.06
-0.0200 (-1.85%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.05 +1.94%
- Market cap
- $108.16m
- P/E
- –
- EPS, last 4 quarters
- $-0.6400
- Dividend yield
- –
- Day range
- $0.9400 to $1.05
- 52-week range
- $0.1952 to $1.79
- Average volume
- 31.80m
- Previous close
- $1.08
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $4.50, +324.5% from here
Earnings
next estimate $-0.0900Next report Nov 12, 2026
Sep 2025
+9.5%
Dec 2025
+30.0%
Mar 2026
+13.3%
Jun 2026
-38.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$8.14m | -$6.67m | -$6.52m | -$6.50m |
| Net income | -$9.01m | -$7.56m | -$7.35m | -$9.75m |
News
8 latest- PDS Biotechnology (PDSB) Just Flashed Golden Cross Signal: Do You Buy?Zacks · 6 days ago
- PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal CancerMarketBeat · Oct 15, 2026
- PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?Zacks · Oct 14, 2026
- Biotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers RTTNews · Sep 15, 2026
- 5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara RTTNews · Sep 8, 2026
- PDS Biotech Raises Up To $22.55M In PIPE Led By Dr. Patrick Soon-Shiong RTTNews · Sep 8, 2026
- PDS Biotech Refocuses On PDS0301 In Colorectal Cancer; Seeks Partners For PDS0101 RTTNews · Aug 11, 2026
- Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom FisherZacks · Jun 10, 2026
The company
PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. PDS Biotechnology owns the Versamune® cancer vaccine platform, including PDS0101, which has been evaluated in HPV16-positive cancers. The Company intends to pursue strategic partnerships or other externally funded opportunities for the Phase 3 development of PDS0101. The Company's lead development program, PDS0301 (also referred to as PDS01ADC & NHS-IL12), is an investigational tumor-targeted interleukin-12 (IL-12) immunocytokine designed to deliver IL-12 preferentially to the tumor microenvironment, with the goal of enhancing anti-tumor immune activity while limiting systemic exposure. PDS0301 has been clinically evaluated across multiple solid tumors, including metastatic colorectal cancer and prostate cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- pdsbiotech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.